1. Home
  2. HRMY vs MIRM Comparison

HRMY vs MIRM Comparison

Compare HRMY & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

HOLD

Current Price

$38.92

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$67.16

Market Cap

3.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HRMY
MIRM
Founded
2017
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
3.4B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
HRMY
MIRM
Price
$38.92
$67.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
11
Target Price
$51.33
$87.55
AVG Volume (30 Days)
789.9K
560.0K
Earning Date
11-04-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
50.44
N/A
EPS
3.17
N/A
Revenue
$825,944,000.00
$471,794,000.00
Revenue This Year
$23.11
$53.78
Revenue Next Year
$16.15
$19.91
P/E Ratio
$12.79
N/A
Revenue Growth
21.13
53.66
52 Week Low
$25.52
$36.88
52 Week High
$40.93
$78.55

Technical Indicators

Market Signals
Indicator
HRMY
MIRM
Relative Strength Index (RSI) 67.44 45.04
Support Level $38.12 $63.23
Resistance Level $40.87 $66.77
Average True Range (ATR) 1.25 3.05
MACD 0.04 -0.46
Stochastic Oscillator 71.48 32.98

Price Performance

Historical Comparison
HRMY
MIRM

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: